DelveInsight’s “Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Marginal Zone Lymphoma, historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Marginal Zone Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Marginal Zone Lymphoma Market Forecast
Some of the key facts of the Marginal Zone Lymphoma Market Report:
The Marginal Zone Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene’s Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.
In 2023, the United States recorded the highest number of marginal zone lymphoma (MZL) incidence cases among the 7MM, exceeding 8,000 cases. This number is projected to grow throughout the forecast period.
In gender-specific Marginal Zone Lymphoma incidence cases, males represent the predominant group.
In 2023, MALT lymphoma accounted for the largest proportion of incident cases in the US, comprising approximately 70%, followed by SMZL and NMZL.
In the US in 2023, stage-specific incidence of Marginal Zone Lymphoma was highest for Stage III-IV cases, followed by Stage I and Stage II.
YESCARTA and BREYANZI are gaining recognition as promising treatments for MZL, with BREYANZI anticipated to receive approval for third-line (3L+) MZL cases by 2026.
Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
The Marginal Zone Lymphoma epidemiology based on gender analyzed that a higher number of males were affected by this disease, i.e., ~54%of the total incident MZL population in the United States, which is equivalent to ~4,300 cases. In comparison to this, for females, the number of cases observed was ~3,700 in 2022.
The Marginal Zone Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Marginal Zone Lymphoma pipeline products will significantly revolutionize the Marginal Zone Lymphoma market dynamics.
Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma, a cancer that originates in white blood cells called lymphocytes. MZL specifically affects a subset of these lymphocytes known as marginal zone B-cells, which are found at the edges, or margins, of lymphoid tissues like the lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT) such as the stomach, salivary glands, or other organs.
Get a Free sample for the Marginal Zone Lymphoma Market Forecast, Size & Share Analysis Report:
http://delveinsight.com/report-store/marginal-zone-lymphoma-market
Marginal Zone Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Marginal Zone Lymphoma Epidemiology Segmentation:
The Marginal Zone Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Marginal Zone Lymphoma
Prevalent Cases of Marginal Zone Lymphoma by severity
Gender-specific Prevalence of Marginal Zone Lymphoma
Diagnosed Cases of Episodic and Chronic Marginal Zone Lymphoma
Download the report to understand which factors are driving Marginal Zone Lymphoma epidemiology trends @ Marginal Zone Lymphoma Epidemiology Forecast
Marginal Zone Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Marginal Zone Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Marginal Zone Lymphoma Therapies and Key Companies
REVLIMID (lenalidomide): Bristol-Myers Squibb
UKONIQ (umbralisib): TG Therapeutics
BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
Yescarta: Gilead Sciences
Calquence: AstraZeneca
Betalutin: Nordic Nanovector
Obinutuzumab: Christian Buske
Rituximab: AbbVie
Ibrutinib: Pharmacyclics LLC
HMPL-689: Hutchison Medipharma
Zanubrutinib: Beigene
tafasitamab: Incyte Corporation
EO2463: Enterome
Discover more about therapies set to grab major Marginal Zone Lymphoma market share @ Marginal Zone Lymphoma Treatment Landscape
Scope of the Marginal Zone Lymphoma Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Marginal Zone Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Marginal Zone Lymphoma Market Access and Reimbursement
To know more about Marginal Zone Lymphoma companies working in the treatment market, visit @ Marginal Zone Lymphoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Marginal Zone Lymphoma Market Report Introduction
2. Executive Summary for Marginal Zone Lymphoma
3. SWOT analysis of Marginal Zone Lymphoma
4. Marginal Zone Lymphoma Patient Share (%) Overview at a Glance
5. Marginal Zone Lymphoma Market Overview at a Glance
6. Marginal Zone Lymphoma Disease Background and Overview
7. Marginal Zone Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Marginal Zone Lymphoma
9. Marginal Zone Lymphoma Current Treatment and Medical Practices
10. Marginal Zone Lymphoma Unmet Needs
11. Marginal Zone Lymphoma Emerging Therapies
12. Marginal Zone Lymphoma Market Outlook
13. Country-Wise Marginal Zone Lymphoma Market Analysis (2020–2034)
14. Marginal Zone Lymphoma Market Access and Reimbursement of Therapies
15. Marginal Zone Lymphoma Market Drivers
16. Marginal Zone Lymphoma Market Barriers
17. Marginal Zone Lymphoma Appendix
18. Marginal Zone Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
